Pharmacological Management of Acute and Chronic Insomnia: A Cross-Sectional Study.

IF 0.8 4区医学 Q4 CLINICAL NEUROLOGY Clinical Neuropharmacology Pub Date : 2024-09-20 DOI:10.1097/WNF.0000000000000611

Luis Fernando Valladales-Restrepo, Nicolás Sánchez-Ramírez, Santiago Ospina-Sánchez, Andrés Felipe Usma-Valencia, Andrés Gaviria-Mendoza, Manuel Machado-Duque, Jorge Enrique Machado-Alba

{"title":"Pharmacological Management of Acute and Chronic Insomnia: A Cross-Sectional Study.","authors":"Luis Fernando Valladales-Restrepo, Nicolás Sánchez-Ramírez, Santiago Ospina-Sánchez, Andrés Felipe Usma-Valencia, Andrés Gaviria-Mendoza, Manuel Machado-Duque, Jorge Enrique Machado-Alba","doi":"10.1097/WNF.0000000000000611","DOIUrl":null,"url":null,"abstract":"Objective: Insomnia is a frequent and difficult disease to treat. The objective was to determine the pharmacological management of a group of patients diagnosed with acute and chronic insomnia.Methods: This is a cross-sectional study that identified patterns of prescription of drugs for outpatient use in patients with insomnia from a population database of 8.5 million individuals in the Health System of Colombia. Sociodemographic and pharmacological variables were considered.Results: A total of 5825 patients with insomnia were identified. Acute insomnia was the most frequent complaint (85.2%). A total of 76.9% received pharmacological treatment, mainly through off-label drugs (70.7%), such as trazodone (20.2%), quetiapine (12.3%), and clonazepam (11.1%). The approved drugs were used in 9.9% of the patients, especially eszopiclone (4.7%) and zopiclone (3.6%). Benzodiazepines and Z compounds predominated in the elderly and individuals with chronic insomnia.Conclusions: The pharmacological treatment of insomnia in this group of patients is heterogeneous, and medications not approved for this indication are very frequently used.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000611","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Insomnia is a frequent and difficult disease to treat. The objective was to determine the pharmacological management of a group of patients diagnosed with acute and chronic insomnia.

Methods: This is a cross-sectional study that identified patterns of prescription of drugs for outpatient use in patients with insomnia from a population database of 8.5 million individuals in the Health System of Colombia. Sociodemographic and pharmacological variables were considered.

Results: A total of 5825 patients with insomnia were identified. Acute insomnia was the most frequent complaint (85.2%). A total of 76.9% received pharmacological treatment, mainly through off-label drugs (70.7%), such as trazodone (20.2%), quetiapine (12.3%), and clonazepam (11.1%). The approved drugs were used in 9.9% of the patients, especially eszopiclone (4.7%) and zopiclone (3.6%). Benzodiazepines and Z compounds predominated in the elderly and individuals with chronic insomnia.

Conclusions: The pharmacological treatment of insomnia in this group of patients is heterogeneous, and medications not approved for this indication are very frequently used.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

急性和慢性失眠症的药物治疗：一项横断面研究

目的：失眠是一种多发病，也是一种难以治疗的疾病。目的是确定一组被诊断为急性和慢性失眠症患者的药物治疗情况：这是一项横断面研究，从哥伦比亚卫生系统的 850 万人口数据库中找出失眠症患者门诊用药处方的模式。研究还考虑了社会人口学和药物学变量：结果：共发现 5825 名失眠症患者。急性失眠是最常见的主诉（85.2%）。76.9%的患者接受了药物治疗，主要是通过标签外药物（70.7%），如曲唑酮（20.2%）、喹硫平（12.3%）和氯硝西泮（11.1%）。9.9%的患者使用了批准药物，尤其是艾佐匹克隆（4.7%）和佐匹克隆（3.6%）。苯二氮卓类药物和Z化合物主要用于老年人和慢性失眠症患者：这组患者的失眠症药物治疗方法多种多样，未被批准用于该适应症的药物被频繁使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Neuropharmacology 医学-临床神经学

CiteScore

1.20

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.